Press release from Companies
Publicerat: 2018-02-16 08:24:44
NextCell Pharma AB ("NextCell") announces that the company has filed a patent application to the Swedish Patent and Registration Office. The patent application relates to the Company's proprietary selection algorithm and formulation of the stem cell drug candidate ProTrans.
The selection algorithm is based on multiple functional assays used to identify and select cells and donors with
specified desired characteristics. ProTrans is a pooled allogeneic stem cell product, consisting of cells from multiple
donors. The pooling process supports the production of large batches. The combination selection algorithm and
pooling of donors supports our strategy to robust production of a high-quality drug product. Together with our
contract manufacturing organization, PBKM, we are enabling large scale production of potent ProTrans.
The patent application is written in a general manner for production of any mesenchymal stem cell product, derived
from multiple donors and cells which have been selected using our selection algorithm. Furthermore, it specifically
focuses on umbilical cord tissue derived stem cells to treat inflammatory and autoimmune diseases, and specifically
type 1 diabetes for which a clinical study is ongoing.
This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse
Regulation. The information was provided by the below contact person for publication on February 16th, 2018.For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Leo Groenewegen, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com
www.nextcellpharma.com (http://file//hm.local/sedermera.se/gemensam/Corp/Externa/NextCell Pharma/KOM/Pressmeddelanden/170713 - Första dag för handel/www.nextcellpharma.com)About NextCell Pharma AB:
Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell Pharma AB develops ProTrans™, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans™ consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.
